500 mg (95% curcumin, 5% desmethoxycurcumin) twice per day for 2 weeks.

Cytotoxicity of compound 7 (Demethoxycurcumin) were evaluated against a panel of 8 cancer cell lines; lung (A549), prostate (DU-145), skin (SK-MEL-5), pancreatic (BxPC-3), liver (Hep G2), colon (HT-29), breast (MCF-7) and (MDA-MB-231). Cell lines were cultured in DMEM media supplemented with 2 mM L-glutamine, 10% fetal bovine serum, 50 mkg/ml gentamycin and 2.5 mkg/ml amphotericin B, maintained in a 37 C humid atmosphere of 5% CO2 cell incubator. Samples and drug standards (cisplatin and vinblastine sulfate) were dissolved in DMSO and immediately diluted with DMEM media to yield a final DMSO concentration of less than 0.5% v/v. Cells were plated into 96-well microplates at 5,000–10,000 cells per well and maintained in the cell incubator for 24 h. Then, 100 mkL of samples were introduced in triplicates to a final concentration of 15–150 mkM. Drug standards were also introduced to a final concentration of 0.03–2000 mkM (cisplatin) and 0.002–100 mkM (vinblastine sulfate). Cells were further incubated for 48 h and then, cell viability was determined according to the manufacturer protocol of a commercial MTS assay kit